Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]

Erlotinib, Hydrochloride Salt

based on 2 citations in multiple journalsErlotinib, Hydrochloride Salt24.1 4
An EGFR kinase inhibitor
Catalog #: 1588
SKU-Size Size Price Qty
1588-100 100 mg
1588-1000 1 g
More Sizes Get Quote

Product Details

Alternate Name CP-358774, OSI-774
Appearance White to off-white solid
CAS # 183319-69-9
Molecular Formula C₂₂H₂₃N₃O₄.HCl
Molecular Weight 429.9
Purity ≥99% by HPLC
Solubility DMSO
InChi InChI=1S/C22H23N3O4.ClH/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H
PubChem CID 176871
MDL Number MFCD07781272
Handling Protect from light and moisture
Storage Conditions -20°C
Shipping Conditions RT
USAGE For Research Use Only! Not For Use in Humans.


Erlotinib is an inhibitor of human Epidermal growth factor receptor (EGFR) tyrosine kinase (IC₅₀ = 2 nM) and decreases EGFR autophosphorylation in tumor cells (IC₅₀ = 20 nM). Studies in cell lines and enzyme assays have both shown that erlotinib inhibits EGFR at concentrations significantly lower than those needed to inhibit c-src and v-abl.

Why buy BioVision Products?
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.
Cheng et al., The TWEAK Receptor Fn14 Is an Src-Inducible Protein and a Positive Regulator of Src-Driven Cell Invasion. Mol. Cancer Res., Mar 2015; 13: 575 - 583.
Dayekh et al., Monensin Inhibits Epidermal Growth Factor Receptor Trafficking and Activation: Synergistic Cytotoxicity in Combination with EGFR Inhibitors. Mol. Cancer Ther., Nov 2014; 13: 2559 - 2571.
For more citations of this product click here